Cue Biopharma Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net loss | $(31,178) | $(37,299) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 299 | 443 |
| Stock-based compensation | 5,284 | 6,108 |
| Decrease in the carrying amount of right-of-use-assets | 2,289 | 2,142 |
| Gain on sale of property and equipment | (97) | (2) |
| Amortization of premium/discount on purchased securities | — | (234) |
| Amortization of debt issuance costs | 28 | 28 |
| Accretion of final payment on term loans | 98 | 98 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (1,454) | (1,603) |
| Prepaid expenses and other current assets | (442) | (324) |
| Deposits | — | 139 |
| Accounts payable | 2,972 | (251) |
| Accrued expenses | (938) | 1,573 |
| Research and development contract liability | (1,853) | 2,238 |
| Operating lease liability | (2,309) | (2,064) |
| Accrued interest | — | 5 |
| Net cash used in operating activities | (27,301) | (29,003) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (64) | — |
| Cash received from the sale of property and equipment | 97 | 2 |
| Redemption of marketable securities | — | 25,000 |
| Net cash provided by investing activities | 33 | 25,002 |
| Cash flows from financing activities | ||
| Proceeds from ATM offering, net of sales agent commission and fees | 3,354 | 7,605 |
| Proceeds from issuance of common stock, warrants and pre-funded warrants, net of transaction costs | 10,821 | — |
| Repayment of term loans | (3,000) | (1,000) |
| Proceeds from exercise of stock options | — | 473 |
| Net cash provided by financing activities | 11,175 | 7,078 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (16,093) | 3,077 |
| Cash, cash equivalents, and restricted cash at beginning of period | 48,665 | 51,764 |
| Cash, cash equivalents, and restricted cash at end of period | $32,572 | $54,841 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Cash paid for interest | $547 | $768 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.